Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...
Eli Lilly’s Full-Year Profit Views in Line After Recent Misses
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...
STAT22d
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...
FierceBiotech24d
JPM25: Eli Lilly strikes $2.5B Scorpion buyout in twist to breast cancer tale
Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...
Wall Street Journal22d
Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs
Eli Lilly LLY-0.39%decrease; red down pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...
Business Insider9d
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...